Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hepatology
•
Autoimmune Liver Disease
What early response criteria and timeframe do you use to declare corticosteroid non-response and move to expedited transplant listing in patient with acute severe AIH without encephalopathy?
Related Questions
In AIH/PBC overlap with both hepatitis and cholestasis, how do you determine whether incomplete biochemical response at 6–12 months reflects undertreated AIH versus inadequately controlled cholestasis?
What is your strategy in the management of patients with autoimmune hepatitis who failed azathioprine therapy and what parameters do you monitor with what frequency?
How do you manage liver enzyme elevations in patients with PBC after starting elanifibranor?
How do you approach restarting immunotherapy in a patient with metastatic melanoma who previously developed immune-mediated hepatitis (Grade 3), with liver enzymes now back to baseline levels?
How do you prefer to manage IgG-4 related hepato-biliary disease, especially if there are similarities in imaging findings to other immune mediated liver diseases?
What patient factors guide your selection of maintenance therapies for a patient with autoimmune hepatitis?
In what clinical scenario would you consider the use of budesonide over prednisone as part of the pharmacologic management of autoimmune hepatitis?
For suspected drug-induced autoimmune-like hepatitis after the culprit drug is stopped and there is no advanced fibrosis, how do you decide immunosuppression duration and the relapse-free follow-up interval needed to confidently label it DI-ALH rather than classic AIH?
What is your strategy to manage pruritus in patients with cholestatic liver disease?
In a serologic evaluation for immune-mediated liver disease, what further workup do you pursue when low immunoglobulins are identified?
